Verily has taken part in an oversubscribed series B round that will fund the UC Berkeley spinout's expansion from diagnostics to gene editing and drug development.
Mammoth Biosciences, a US-based disease diagnostics technology spinout from University of California (UC) Berkeley, secured $45m in series B funding on Thursday led by life sciences investment firm Decheng Capital.
Verily, the life sciences research subsidiary of technology conglomerate Alphabet, also contributed to the round, as did Mayfield, NFX, Plum Alley Investments, Pacific 8 Ventures, aMoon and private investor Brook Byers.
Mammoth is developing disease detection systems using Crispr DNA technology, although it focuses on the Cas14 enzyme…
